Rosiglitazone Adjunctive Therapy for Severe Malaria in Children
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Even with optimal anti-malaria therapy and supportive care, severe and cerebral malaria are
associated with a 10-30% mortality rate and neurocognitive deficits in up to 33% of
survivors. Adjunctive therapies that modify host immune-pathological processes may further
improve outcome over that possible with anti-malarials alone. Investigators aim to evaluate a
PPARĪ³ agonist ( "rosiglitazone") as adjunctive therapy for severe malaria.
Phase:
N/A
Details
Lead Sponsor:
Centro de Investigacao em Saude de Manhica
Collaborators:
Barcelona Institute for Global Health University Health Network, Toronto